Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
Senolytic and senomorphic therapies are advancing with compounds like RLS-1496 and α-ESA-me targeting senescent cells. Experts highlight challenges in biomarkers and safety, pushing for personalized ...
Emerging research shows that enhancing mRNA surveillance mechanisms like nonsense-mediated decay can reduce neurodegeneration, with innovative therapies targeting tau aggregation offering new hope. Re...
Recent studies from the LEV Foundation and Brian Kennedy’s team show that combining therapies targeting multiple age-related damages can significantly extend lifespan and healthspan in preclinic...
Recent geriatric research finds positive age beliefs can boost cognitive and physical function by up to 40%, with practical strategies like mindfulness and social engagement supported by new data. New...
Recent studies reveal that mild stressors like hypoxia enhance autophagy and epigenetic changes, delaying aging and informing lifestyle interventions and drug development for preventive health. Emergi...
Recent 2023 research shows age-related gut microbiome shifts drive brain inflammation and cognitive decline, with fecal microbiota transplantation and anti-inflammatory diets emerging as promising ant...
A groundbreaking study reveals centenarians’ unique chromatin accessibility in immune cells, with ERG reducing cellular senescence and boosting immune resilience, pointing to new epigenetic inte...
Recent advancements in cellular reprogramming, including significant funding and clinical trials, are transforming anti-aging science by targeting root causes of age-related diseases. Cellular reprogr...
Recent advances in partial cellular reprogramming using OSKM factors show promise in extending healthspan and treating age-related diseases, with biotech firms accelerating towards human trials. New r...
